Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | PLAT | P00750 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL256938 | 0.86 | NPC1 (0.74) | NPC1RAB9APLATCYP1A2PARP1 | |
| SCHEMBL257549 | 0.83 | NPC1 (0.74) | NPC1RAB9APLATCYP1A2PARP1 | |
| SCHEMBL257310 | 0.82 | NPC1 (0.68) | NPC1RAB9APLATCYP1A2PARP1 | |
| SCHEMBL257543 | 0.80 | NPC1 (0.77) | NPC1RAB9APLATCYP1A2PARP1 | |
| SCHEMBL15020774 | 0.76 | NPC1 (0.60) | NPC1RAB9APLATCYP1A2PARP1 | |
| SCHEMBL461719 | 0.71 | NPC1 (0.59) | NPC1RAB9ACYP1A2PARP1KDM4E | |
| SCHEMBL17731131 | 0.69 | PLAT (0.71) | NPC1RAB9APLAT | |
| SCHEMBL10072287 | 0.69 | TP53 (0.46) | NPC1RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL5461696 | 0.68 | NPC1 (0.56) | NPC1RAB9ACYP1A2PARP1KDM4E | |
| SCHEMBL3488854 | 0.68 | KCNH2 (0.50) | NPC1RAB9AKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975264-B2 | Compound acting as a cannabinoid receptor-1 inhibitor | AMOREPACIFIC CORPORATION (KR) | 2015-03-10 | — | — | US | disclosed |
| US-8975264-B2 | Compound acting as a cannabinoid receptor-1 inhibitor | AMOREPACIFIC CORPORATION (KR) | 2015-03-10 | — | — | US | disclosed |
| EP-2617723-A2 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | Amorepacific Corporation (KR) | 2013-07-24 | — | — | EP | disclosed |
| US-20130158025-A1 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | AMOREPACIFIC CORPORATION (KR) | 2013-06-20 | — | — | US | disclosed |
| US-20130158025-A1 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | AMOREPACIFIC CORPORATION (KR) | 2013-06-20 | — | — | US | disclosed |
| WO-2012030170-A2 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | (주)아모레퍼시픽 (KR) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158025-A1 | NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR | CNR1, CNR2, GPR18 | NPC1 114/4885RAB9A 542/4885PLAT 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.